ArticleCancers2022
Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Thermal Ablation for Colorectal Liver Metastases: Current Evidence and Future Horizons.Diagnostics (Basel, Switzerland) · 2026Review
- Repeat ablation and single-session ablation in patients with multiple colorectal cancer liver metastases after chemotherapy failure.World journal of gastroenterology · 2025Article
- Article
- Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.Biomedicines · 2025Review
- Review
- Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases.Cytotechnology · 2025Article
- Optimizing extended ablation margins in papillary thyroid carcinoma using digital pathology.Frontiers in endocrinology · 2025Article
- Pre-operative lung ablation prediction using deep learning.European radiology · 2024Article
- Oncologic Outcomes after Percutaneous Ablation for Colorectal Liver Metastases: An Updated Comprehensive Review.Medicina (Kaunas, Lithuania) · 2024Review
- Review
- Advancements and Future Outlook of PET/CT-Guided Interventions.Techniques in vascular and interventional radiology · 2023Review
- Ablative Margins of Colorectal Liver Metastases Using Deformable CT Image Registration and Autosegmentation.Radiology · 2023Article
- Article
- Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies.Cancers · 2023Review
- Predictive Factors for Local Recurrence after Intraoperative Microwave Ablation for Colorectal Liver Metastases.Cancers · 2022Article
- Article
- Interstitial Photothermal Therapy Generates Durable Treatment Responses in Neuroblastoma.Advanced healthcare materials · 2022Article
- 3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThermal ablation is a definitive local treatment for selected colorectal liver metastases (CLM) that can be ablated with adequate margins. A critical limitation has been local tumor progression (LTP).
methodsThis prospective, single-group, phase 2 study enrolled patients with CLM < 5 cm in maximum diameter, at a tertiary cancer center between November 2009 and February 2019. Biopsy of the ablation zone center and margin was performed immediately after ablation. Viable tumor in tissue biopsy and ablation margins < 5 mm were assessed as predictors of 12-month LTP.
resultsWe enrolled 107 patients with 182 CLMs. Mean tumor size was 2.0 (range, 0.6-4.6) cm. Microwave ablation was used in 51% and radiofrequency ablation in 49% of tumors. The 12- and 24-month cumulative incidence of LTP was 22% (95% confidence interval [CI]: 17, 29) and 29% (95% CI: 23, 36), respectively. LTP at 12 months was 7% (95% CI: 3, 14) for the biopsy tumor-negative ablation zone with margins ≥ 5 mm vs. 63% (95% CI: 35, 85) for the biopsy-positive ablation zone with margins < 5 mm (
conclusionsBiopsy-proven complete tumor ablation with margins of at least 5 mm achieves optimal local tumor control for CLM, regardless of the ablation modality used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.